P/E ratio for Zeria Pharmaceutical (4559.T)
P/E ratio as of March 2025 (TTM): 11.2
According to Zeria Pharmaceutical's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 11.1562. At the end of 2023 the company had a P/E ratio of 15.8.
P/E ratio history for Zeria Pharmaceutical from 2009 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2023 | 15.8 | -28.95% |
| 2022 | 22.3 | -30.57% |
| 2021 | 32.1 | -8.54% |
| 2020 | 35.1 | 24.71% |
| 2019 | 28.1 | 6.72% |
| 2018 | 26.4 | 0.07% |
| 2017 | 26.3 | 16.88% |
| 2016 | 22.5 | -45.84% |
| 2015 | 41.6 | 129.69% |
| 2014 | 18.1 | 19.72% |
| 2013 | 15.1 | -28.9% |
| 2012 | 21.3 | -4.49% |
| 2011 | 22.3 | -44.88% |
| 2010 | 40.4 | 8.05% |
| 2009 | 37.4 | 37.58% |
| 2008 | 27.2 | 24.82% |
| 2007 | 21.8 | -41.34% |
| 2006 | 37.2 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.